{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "60001116",
    "licUnit": "1",
    "validDate": "2029-12-11 00:00:00.000",
    "issueDate": "2019-12-11 00:00:00.000",
    "oriIssueDate": "2019-12-11",
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA06000111603",
    "prodNameC": "赫珠瑪 凍晶注射劑440毫克",
    "prodNameE": "Herzuma Inj. 440mg, Lyophilized powder for injection",
    "indicationsName": [
        "(一)使用於下列HER2 過度表現或HER2 基因amplification 之早期乳癌、轉移性乳癌病人。\r\n1. 早期乳癌(EBC)\r\n(1) 經外科手術、化學療法 (術前或術後) 之輔助療法。\r\n(2) 以doxorubicin與cyclophosphamide 治療，再合併paclitaxel 或docetaxel 之輔助療法。\r\n(3) 與 docetaxel及carboplatin 併用之輔助療法。\r\n(4) 術前與化學療法併用和術後之輔助療法使用於治療局部晚期(包括炎症)乳癌或腫瘤(直徑>2 厘米)。\r\n2. 轉移性乳癌(MBC)\r\n(1) 單獨使用於曾接受過一次 (含) 以上化學療法之轉移性乳癌；除非病人不適合使用anthracycline或taxane，否則先前之化學治療應至少包括anthracycline或taxane。使用於荷爾蒙療法失敗之荷爾蒙受體陽性之病人，除非病人不適用荷爾蒙療法。\r\n(2) 與paclitaxel或docetaxel併用於未曾接受過化學療法之轉移性乳癌。\r\n(3) 與芳香環酶抑制劑併用於荷爾蒙受體陽性之轉移性乳癌。\r\n(二) 轉移性胃癌 (mGC)\r\n合併capecitabine (或5-fluorouracil) 及 cisplatin 適用於未曾接受過化學治療之HER2過度表現轉移性胃腺癌 (或胃食道接合處腺癌) 的治療。"
    ],
    "does": "2243",
    "packageUnit": [
        {
            "packageSpec": "440毫克玻璃小瓶裝附溶劑20毫升，100支以下",
            "packageUnit": "03"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": "D",
    "mainCategory": "D",
    "drBaseId": "DA29D990-B7CC-4D9F-9798-06E0D00E7E53",
    "subCategory": [],
    "ingredientsDesc": [
        "Trastuzumab"
    ],
    "restraintItemsCode": [
        "02 輸 入",
        "07 新藥監視",
        "1D 須執行風險管理計畫",
        "68 成品已完成元素不純物評估(Option 3)",
        "91 生物相似性藥品"
    ],
    "applicantName": "台灣賽特瑞恩有限公司",
    "applicantAddr": "臺北市信義區松仁路97號3樓之1",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": "",
    "mdKind": [],
    "monitorDate": "2024-12-11",
    "licidNew": null,
    "licidOld": null,
    "factoryDtoList": [
        {
            "id": "46FD1EFE-258D-4B1F-8613-5375E1CBEE55",
            "factoryCode": "1",
            "factoryName": "CELLTRION INC.",
            "factoryAddr": "20, ACADEMY-RO, 51BEON-GIL, YEONSU-GU, INCHEON, 22014, REPUBLIC OF KOREA",
            "factoryCompanyAddr": null,
            "countryCode": "KR",
            "processCode": [
                {
                    "value": "2I",
                    "name": "原料藥及成品製造廠"
                }
            ],
            "processCodeStr": "2I;原料藥及成品製造廠",
            "factoryKind": "M",
            "factoryNo": "FKR0182100",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "A647A1C9-28B0-45B1-AC77-5FF8B284BEA0",
            "factoryCode": "2",
            "factoryName": "CELLTRION INC.",
            "factoryAddr": "23, ACADEMY-RO, YEONSU-GU, INCHEON, 22014, REPUBLIC OF KOREA",
            "factoryCompanyAddr": null,
            "countryCode": "KR",
            "processCode": [
                {
                    "value": "2L",
                    "name": "公司"
                }
            ],
            "processCodeStr": "2L;公司",
            "factoryKind": "M",
            "factoryNo": "FKR0182000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013004800",
            "ingredientsName": "Trastuzumab",
            "ingredientsDesc": "Trastuzumab",
            "concentDesc": "",
            "concent": "440.000000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FD01"
        }
    ],
    "licBaseId": "80FFCE6D-663D-40CF-8815-D3A24EF6F063"
}